PMID- 34643766
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 71
IP  - 5
DP  - 2022 May
TI  - Assessment of immune status of laryngeal squamous cell carcinoma can predict 
      prognosis and guide treatment.
PG  - 1199-1220
LID - 10.1007/s00262-021-03071-7 [doi]
AB  - BACKGROUND: In the past few years, immunotherapy has changed the way we treat 
      solid tumors. People pay more and more attention to the immune microenvironment 
      of laryngeal squamous cell carcinoma (LSCC). In this study, our immunotherapy 
      research took advantage of the clinical database and focused our in-depth 
      analysis on the tumor microenvironment (TME). METHODS: This study evaluated the 
      relationship between the clinical outcome and the local tissue and overall immune 
      status in 412 patients with primary LSCC. We constructed and validated a risk 
      model that could predict prognosis, assess immune status, identify high-risk 
      patients, and develop personalized treatment plans through bioinformatics. In 
      addition, through immunohistochemical analysis, we verified the differential 
      expression of CTSL and KDM5D genes with the largest weight coefficients in the 
      model in LSCC tissues and their influence on the prognosis and tumor-infiltrating 
      lymphocytes (TILs). RESULTS: We found that interstitial tumor-infiltrating 
      lymphocytes, tumor parenchymal-infiltrating lymphocyte volume, tumor infiltrates 
      lymphocytes of frontier invasion, and the platelet-to-lymphocyte ratio (PLR) were 
      independent factors affecting the prognosis of patients with LSCC. A novel risk 
      model can guide clinicians to accurately predict prognosis, identify high-risk 
      patients, and formulate personalized treatment plans. The differential expression 
      of genes such as CTSL and KDM5D has a significant correlation with the TILs of 
      LSCC and the prognosis of patients. CONCLUSION: Local and systemic inflammatory 
      markers in patients with laryngeal squamous cell carcinoma are reliable 
      prognostic factors. The risk model and CTSL, KDM5D gene have important potential 
      research value.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Wang, Xueying
AU  - Wang X
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Cao, Kui
AU  - Cao K
AD  - Department of Laboratory, Harbin Medical University Cancer Hospital, Harbin, 
      150081, China.
FAU - Guo, Erliang
AU  - Guo E
AD  - Department of Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 
      Harbin, 150081, China.
FAU - Mao, Xionghui
AU  - Mao X
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - An, Changming
AU  - An C
AD  - Department of Head and Neck Surgery, Chinese National Cancer Center &, Chinese 
      Academy of Medical Sciences Cancer Hospital, Beijing, China.
FAU - Guo, Lunhua
AU  - Guo L
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Zhang, Cong
AU  - Zhang C
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Guo, Junnan
AU  - Guo J
AD  - Department of Colorectal Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Yang, Xianguang
AU  - Yang X
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Sun, Ji
AU  - Sun J
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China.
FAU - Yang, Weiwei
AU  - Yang W
AD  - Department of Pathology, Harbin Medical University, Harbin, 150081, China.
FAU - Li, Xiaomei
AU  - Li X
AD  - Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, 
      150081, China. fanliwenqi@163.com.
FAU - Miao, Susheng
AU  - Miao S
AUID- ORCID: 0000-0002-7701-9362
AD  - Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, 
      Harbin, 150081, China. drmiaosusheng@126.com.
LA  - eng
GR  - LBH-Q18088/heilongjiang provincial postdoctoral science foundation/
PT  - Journal Article
DEP - 20211013
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - EC 1.14.11.- (Histone Demethylases)
RN  - EC 1.14.11.- (KDM5D protein, human)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - *Head and Neck Neoplasms/pathology
MH  - Histone Demethylases
MH  - Humans
MH  - *Laryngeal Neoplasms/genetics/therapy
MH  - Lymphocytes, Tumor-Infiltrating
MH  - Minor Histocompatibility Antigens
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck/pathology
MH  - Tumor Microenvironment
PMC - PMC10992030
OTO - NOTNLM
OT  - Immunotherapy
OT  - Infiltrating lymphocyte volume (TILv)
OT  - Intratumoral infiltrating lymphocytes (iTILs)
OT  - Laryngeal squamous cell carcinoma (LSCC)
OT  - Tumor infiltrates lymphocytes of frontier invasion (TILf)
COIS- The authors declare that they have no competing interests.
EDAT- 2021/10/14 06:00
MHDA- 2022/04/21 06:00
PMCR- 2021/10/13
CRDT- 2021/10/13 12:25
PHST- 2021/07/13 00:00 [received]
PHST- 2021/09/27 00:00 [accepted]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
PHST- 2021/10/13 12:25 [entrez]
PHST- 2021/10/13 00:00 [pmc-release]
AID - 10.1007/s00262-021-03071-7 [pii]
AID - 3071 [pii]
AID - 10.1007/s00262-021-03071-7 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2022 May;71(5):1199-1220. doi: 
      10.1007/s00262-021-03071-7. Epub 2021 Oct 13.